Anifrolumab: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Anifrolumab appears in the FDA drug-label database. Marketed as SAPHNELO.
- Drug class
- Type I Interferon Receptor Antagonist (FDA established pharmacologic class)
- Mechanism of action
- Type I Interferon Receptor Antagonists (as stated on the FDA label)
FDA-approved use
SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. Limitations of Use The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. SAPHNELO is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. ( 1 ) Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. ( 1 )
Phase breakdown
Conditions being studied
Recruiting trials involving Anifrolumab
- A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
- An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Anifrolumab Malignancy and Serious Infections Study
- Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
- Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
- The Anifrolumab PRIM Program
- The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Common questions
Is Anifrolumab FDA-approved?
Yes, marketed as SAPHNELO.
How many recruiting trials involve Anifrolumab?
8 recruiting trials across 5 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.